Navigating adalimumab biosimilars: an expert opinion
The patent expiry of Humira in 2018 opened up the current European market to eight adalimumab biosimilars - (in alphabetical order) Amgevita, Amsparity, Hulio, Hukyndra, Hyrimoz, Idacio, Imraldi and Yuflyma - for the treatment of various immune and inflammatory conditions. Amjevita, Hadlima, Hyrimoz...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Becaris Publishing Limited,
2023-10-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Primjerak 1 | Dostupno |